Immunotherapy for Infectious Diseases
Immunotherapy for Infectious Diseases Immunotherapy for Infectious Diseases
Index 331 dendritic cell response, 103 epidemiology, 283 human immunodeficiency virus opportunistic infection, 286, 287, 290, 294 immunopathogenesis, 285, 286 macrophage activation in host response, 283–285 public health challenges, 283 reactivation risk factors, 283 Vaccine, cell types in immune response, 130, 133 cytotoxic T-lymphocyte response, dendritic cell vaccines, 265 genetic immunization, 263–265 peptides, 263 DNA vaccines, advantages, 140 disadvantages, 140, 141 immune response, 139 principles, 139, 263–265 types, 140 Epstein-Barr virus, 267 hepatitis B, 269 historical perspective, 129 human immunodeficiency virus, 188–190, 230 human papillomavirus, 268 ideal properties, 130, 131 immunotherapeutic vaccines, 145 inactivated vaccines, advantages, 132, 133 disadvantages, 133 humoral response, 132 requirements, 131 types, 133 internal image idiotype vaccine, advantages, 136 disadvantages, 136 immune response, 136 principles, 135 types, 137 live attenuated vaccines, advantages, 135 disadvantages, 135 immune response, 134, 135 production, 134 peptide-based vaccines, advantages, 134 delivery of T-cell peptides by recombinant proteins, 142, 143 disadvantages, 134 immune response, 141, 142 principles, 141 receptor-mediated delivery of peptides, 134 self molecule delivery of peptides, 144 viruses expressing foreign epitopes, 141, 142 Pythium insidisum vaccine, 311, 312 recombinant protein vaccines, advantages, 137 disadvantages, 137 immune response, 137 production, 136, 137 recombinant vector vaccines, adenovirus vectors, 138 Bacillus anthracis vector, 139 BCG vectors, 139 Salmonella vectors, 138, 139 vaccinia vectors, 138 subunit vaccines, advantages, 134 disadvantages, 134 immune response, 134 production, 134 tuberculosis vaccination with Mycobacterium vaccae, 292, 293 Varicella-zoster virus, immunoglobulin therapy, 72, 74
Infectious Disease IMMUNOTHERAPY FOR INFECTIOUS DISEASES ISBN: 0-89603-669-3 humanapress.com INFECTIOUS DISEASE VASSIL ST. GEORGIEV, Series Editor Immunotherapy for Infectious Diseases Edited by Jeffrey M. Jacobson, MD Mount Sinai School of Medicine, New York, NY Because the search for safe and effective chemotherapeutic agents has been hindered by antimicrobial resistance and toxic harm, there is a growing need to understand how the immune system can be manipulated to control infections, particularly HIV. In Immunotherapy for Infectious Diseases, Jeffrey M. Jacobson, MD, and a group of leading researchers active in the field review the state-of-the-art for treating various infections—particularly HIV—by manipulating the immune system’s response rather than by using chemical drugs. The contributors synthesize the principles of immune defense on the molecular level (monoclonal antibodies, vaccines, methods of antigen presentation, and cytokines and cytokine antagonists), as well as on the cellular and clinical levels as a protection against infection. The review of the current state of anti-HIV immunotherapy covers HIV-specific passive and active immunization strategies, gene therapy, and host cell–targeted approaches for treating HIV infection and restoring immune function. Also discussed are immunotherapy for other viral infections, virus-associated malignancies, bacterial infections and sepsis, tuberculosis, and fungal infections. Comprehensive and cutting-edge, Immunotherapy for Infectious Diseases reviews all the current stateof-the-art developments occurring in this rapidly evolving field and helps set the stage for the early development of better immunologically based therapies for infections. • State-of-the-art for treating infections by manipulating immune system response • Review of the basic principles of immune defense at the molecular, cellular, and clinical levels I Basic Principles of Immunity. Humoral Immunity. Some Basic Cellular Immunology Principles Applied to the Pathogenesis of Infectious Diseases. Immune Defense at Mucosal Surfaces. II Molecular Basis for Immunotherapy. Production of Immunoglobulins and Monoclonal Antibodies Targeting Infectious Diseases. Dendritic Cells: Their Role in the Immune Response to Infectious Organisms and Their Potential Use in Therapeutic Vaccination. Cytokines, Cytokine Antagonists, and Growth Factors for Treating Infections. Principles of Vaccine Development. III Immunotherapy for HIV Infection. Immunopathogenesis of HIV Infection. Features Contents • Emphasis on anti-HIV immunotherapies • Additional coverage of immunotherapy for viral, bacterial, and fungal infections Immune Reconstitution with Antiretroviral Chemotherapy. Active Immunization as Therapy for HIV Infection. Passive Immunotherapy for HIV Infection. Host Cell-Directed Approaches for Treating HIV and Restoring Immune Function. Gene Therapy for HIV-1 Infection. IV Immunotherapy for Infectious Diseases Other Than HIV. Immunotherapy for Viral Infections Other Than HIV. Immunotherapy for Virus-Associated Malignancies. Immunotherapy of Bacterial Infections and Sepsis. Immunotherapy for Tuberculosis and Other Mycobacterial Infections. Immunotherapy for Fungal Infections. Index. 9 780896 036697 90000
- Page 292: Bacterial Infections and Sepsis 281
- Page 295 and 296: 284 Wallis and Johnson replication
- Page 297 and 298: 286 Wallis and Johnson Several stud
- Page 299 and 300: 288 Wallis and Johnson monocytes, a
- Page 301 and 302: 290 Wallis and Johnson peripheral b
- Page 303 and 304: 292 Wallis and Johnson (A. Hise and
- Page 305 and 306: 294 Wallis and Johnson infections,
- Page 307 and 308: 296 Wallis and Johnson 37. Boom WH.
- Page 309 and 310: 298 Wallis and Johnson 77. Ellner J
- Page 311 and 312: 300 Wallis and Johnson 113. Raad I,
- Page 313 and 314: 302 Wallis and Johnson 154. Anonymo
- Page 315 and 316: 304 Table 1 Major Fungal Infections
- Page 317 and 318: 306 Casadevall species suggest that
- Page 319 and 320: 308 Casadevall transfusions from G-
- Page 321 and 322: 310 Casadevall Table 3 Augmentation
- Page 323 and 324: 312 Casadevall There has been some
- Page 325 and 326: 314 Casadevall effective in achievi
- Page 327 and 328: 316 Casadevall CONCLUSION AND FUTUR
- Page 329 and 330: 318 Casadevall 16. Boutati EI, Anai
- Page 331 and 332: 320 Casadevall 52. Gallin JI, Malec
- Page 333 and 334: 322 Casadevall 91. Kowanko IC, Ferr
- Page 335 and 336: 324 Index Blastomycosis, see Fungal
- Page 337 and 338: 326 Index C-type retrovirus vectors
- Page 339 and 340: 328 Index K Klebsiella, intravenous
- Page 341: 330 Index Vaccine Recombinant vecto
<strong>Infectious</strong> Disease<br />
IMMUNOTHERAPY FOR INFECTIOUS DISEASES<br />
ISBN: 0-89603-669-3<br />
humanapress.com<br />
INFECTIOUS DISEASE<br />
VASSIL ST. GEORGIEV, Series Editor<br />
<strong>Immunotherapy</strong> <strong>for</strong> <strong>Infectious</strong> <strong>Diseases</strong><br />
Edited by<br />
Jeffrey M. Jacobson, MD<br />
Mount Sinai School of Medicine, New York, NY<br />
Because the search <strong>for</strong> safe and effective chemotherapeutic agents has been hindered by antimicrobial<br />
resistance and toxic harm, there is a growing need to understand how the immune system can be<br />
manipulated to control infections, particularly HIV. In <strong>Immunotherapy</strong> <strong>for</strong> <strong>Infectious</strong> <strong>Diseases</strong>, Jeffrey M.<br />
Jacobson, MD, and a group of leading researchers active in the field review the state-of-the-art <strong>for</strong> treating<br />
various infections—particularly HIV—by manipulating the immune system’s response rather than by<br />
using chemical drugs. The contributors synthesize the principles of immune defense on the molecular<br />
level (monoclonal antibodies, vaccines, methods of antigen presentation, and cytokines and cytokine<br />
antagonists), as well as on the cellular and clinical levels as a protection against infection. The review of<br />
the current state of anti-HIV immunotherapy covers HIV-specific passive and active immunization strategies,<br />
gene therapy, and host cell–targeted approaches <strong>for</strong> treating HIV infection and restoring immune<br />
function. Also discussed are immunotherapy <strong>for</strong> other viral infections, virus-associated malignancies,<br />
bacterial infections and sepsis, tuberculosis, and fungal infections.<br />
Comprehensive and cutting-edge, <strong>Immunotherapy</strong> <strong>for</strong> <strong>Infectious</strong> <strong>Diseases</strong> reviews all the current stateof-the-art<br />
developments occurring in this rapidly evolving field and helps set the stage <strong>for</strong> the early<br />
development of better immunologically based therapies <strong>for</strong> infections.<br />
• State-of-the-art <strong>for</strong> treating infections by<br />
manipulating immune system response<br />
• Review of the basic principles of immune defense<br />
at the molecular, cellular, and clinical levels<br />
I Basic Principles of Immunity. Humoral Immunity. Some<br />
Basic Cellular Immunology Principles Applied to the<br />
Pathogenesis of <strong>Infectious</strong> <strong>Diseases</strong>. Immune Defense at<br />
Mucosal Surfaces. II Molecular Basis <strong>for</strong> <strong>Immunotherapy</strong>.<br />
Production of Immunoglobulins and Monoclonal Antibodies<br />
Targeting <strong>Infectious</strong> <strong>Diseases</strong>. Dendritic Cells: Their<br />
Role in the Immune Response to <strong>Infectious</strong> Organisms and Their<br />
Potential Use in Therapeutic Vaccination. Cytokines, Cytokine<br />
Antagonists, and Growth Factors <strong>for</strong> Treating Infections.<br />
Principles of Vaccine Development. III <strong>Immunotherapy</strong><br />
<strong>for</strong> HIV Infection. Immunopathogenesis of HIV Infection.<br />
Features<br />
Contents<br />
• Emphasis on anti-HIV immunotherapies<br />
• Additional coverage of immunotherapy <strong>for</strong> viral,<br />
bacterial, and fungal infections<br />
Immune Reconstitution with Antiretroviral Chemotherapy.<br />
Active Immunization as Therapy <strong>for</strong> HIV Infection. Passive<br />
<strong>Immunotherapy</strong> <strong>for</strong> HIV Infection. Host Cell-Directed<br />
Approaches <strong>for</strong> Treating HIV and Restoring Immune Function.<br />
Gene Therapy <strong>for</strong> HIV-1 Infection. IV <strong>Immunotherapy</strong><br />
<strong>for</strong> <strong>Infectious</strong> <strong>Diseases</strong> Other Than HIV.<br />
<strong>Immunotherapy</strong> <strong>for</strong> Viral Infections Other Than HIV.<br />
<strong>Immunotherapy</strong> <strong>for</strong> Virus-Associated Malignancies. <strong>Immunotherapy</strong><br />
of Bacterial Infections and Sepsis. <strong>Immunotherapy</strong><br />
<strong>for</strong> Tuberculosis and Other Mycobacterial Infections.<br />
<strong>Immunotherapy</strong> <strong>for</strong> Fungal Infections. Index.<br />
9 780896 036697<br />
90000